Medpace Holdings, Inc. (MEDP) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Medpace Holdings, Inc. (MEDP) stock forecast summary
Our AI ranks Medpace Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Medpace Holdings, Inc. is a large-cap company with a market capitalization of $17.26B. It ranks number 3 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its P/B Ratio of 39.79x is the highest of the 10 peers that report one. Its ROE of 113.3% is the highest of the 9 peers that report one.
For MEDP, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 45.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MEDP included.
Follow MEDP freeMEDP price chart and AI forecast
How MEDP ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Medpace Holdings, Inc. (MEDP) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | MEDP | Rank |
|---|---|---|
| Market Cap | $17.26B | 3/15 |
| P/E Ratio | 36.30x | – |
| P/B Ratio | 39.79x | 1/10 |
| EPS | $17.04 | – |
| Book Value/Share | $15.54 | – |
| Revenue/Share | $99.68 | – |
| FCF/Share | $25.32 | – |
Profitability & Margins
| Metric | MEDP | Rank |
|---|---|---|
| ROE | 113.3% | 1/9 |
| ROA | 23.9% | 1/11 |
| ROIC | 93.8% | 1/11 |
| Operating Margin | 21.0% | 2/13 |
| Net Margin | 17.7% | 2/10 |
| EBT Margin | 21.5% | 2/13 |
| Tax Rate | 17.9% | – |
Financial Health
| Metric | MEDP | Rank |
|---|---|---|
| Current Ratio | 0.73x | 10/16 |
| D/E Ratio | 3.74x | 3/11 |
| Financial Leverage | 4.74x | 3/10 |
| Interest Coverage | 733.2x | 1/13 |
| Working Capital | -$385M | 14/15 |
Cash Flow
| Metric | MEDP | Rank |
|---|---|---|
| Operating Cash Flow | $753M | 4/15 |
| Free Cash Flow | $707M | 2/7 |
| Capital Spending | -$46M | 5/7 |
| OCF Growth YoY | 22.6% | 2/5 |
| FCF Growth YoY | 21.9% | – |
| FCF/Sales | 25.4% | 1/8 |
| CapEx/Sales | 1.6% | 6/8 |
Operational Efficiency
| Metric | MEDP | Rank |
|---|---|---|
| Asset Turnover | 1.35x | 1/8 |
| Receivables Turnover | 6.6x | 3/7 |
| Fixed Assets Turnover | 17.7x | 3/9 |
| Days Sales Outstanding | 55 days | 5/7 |
Income Statement
| Metric | MEDP | Rank |
|---|---|---|
| Total Revenue | $2.78B | 4/8 |
| Operating Income | $583M | 4/15 |
| Net Income | $492M | 3/12 |
| SG&A Expense | $189M | 5/12 |
Dividend & Shareholder Information
| Metric | MEDP | Rank |
|---|---|---|
| Shares Outstanding | 28M | – |
| Net Income Growth | 17.5% | – |
| EPS Growth | 26.7% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.05B | 51.1% of assets |
| Cash & Short-term Investments | $503M | 24.4% of assets |
| Accounts Receivable | $421M | 20.4% of assets |
| Total Liabilities | $1.62B | 78.9% of assets |
| Short-term Debt | $1.40B | 68.0% of assets |
MEDP quarterly financials and insider trading
Medpace Holdings, Inc. (MEDP) industry peers
Companies classified under the same SEC industry code as Medpace Holdings, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| INCY Incyte Corp | ▶ | $22.20B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| ICLR Icon Plc | ▶ | $13.13B |
| ABSI Absci Corp | ▲ | $1.42B |
| OABI Omniab, Inc. | ▲ | $667M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $134M |
| ONMD Onemednet Corp | ▲ | $28M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| BUDZ Weed, Inc. | ▲ | $3M |
| ISPC Ispecimen Inc. | ▼ | $3M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
Where MEDP sits on the market map
Medpace Holdings, Inc. (MEDP) stock news
Loading...
Medpace Holdings, Inc. (MEDP) stock forecast FAQ
What is the Medpace Holdings, Inc. (MEDP) stock forecast?
Our AI ranks Medpace Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Medpace Holdings, Inc. stock predictions?
For MEDP, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 45.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Medpace Holdings, Inc. forecasts updated?
Medpace Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Medpace Holdings, Inc.'s industry peers?
16 issuers in our coverage, MEDP included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI), Omniab, Inc. (OABI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.